Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

c-Met May Be a Biomarker for Metastatic Hepatocellular Carcinoma

September 28, 2010 By AACR

Tweet Bookmark and Share

• c-Met activation linked with poor prognosis.

• c-Met was highly overexpressed in metastatic liver cancer cells.

DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.

“Current therapies for HCC patients are ‘one size fits all.’ We propose that molecular profiling will enable better therapy for HCC patients with a c-Met positive tumor,” said Hanning You, M.D., Ph.D., postdoctoral fellow working in the laboratory of C. Bart Rountree, M.D., in the departments of pediatrics and pharmacology, at the Pennsylvania State University College of Medicine, Hershey, Pa.

Using a preclinical translational study to validate c-Met as a target for HCC, You and colleagues found c-Met was highly overexpressed in metastatic liver cancer cells.

“By targeting c-Met we were able to suppress tumor growth in vivo and kill these metastatic liver cancer cells,” said You.

Since c-Met inhibitor stopped proliferation and tumor growth of metastatic HCC cells, the researchers concluded that c-Met might be a potential personalized target of metastatic HCC. In addition, they found that results of a separate meta-analysis of six studies and 1,051 patients showed that c-Met activation is associated with poor prognosis in HCC.

# # #

Follow the AACR on Twitter: @AACR #AACR

Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.

Media Contact:

Jeremy Moore

(267) 646-0557

[email protected]

In Denver, Sept. 27-30:

(303) 352-2464

SOURCE

Related Articles Read More >

The Enterra II gastric electrical stimulation implant system.
FDA puts gastric implants on device shortages list, adds Resmed product discontinuation
An illustration showing the Autus size-adjustable heart valve being expanded years after implantation with a minimally invasive balloon catheter.
The first-of-its-kind Autus pediatric heart valve is designed for expansion and durability
The MIT researcher's implant, LUCID.
MIT researchers design implantable ultrasound-powered drug delivery device to minimize tumor recurrence
An image of the Teleflex Freesolve RMS resorbable magnesium scaffold.
Teleflex Interventional leader sees resorbables as ‘the next frontier’ of PCI
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe